# Lenalidomide in Patients With Chronic Myelomonocytic Leukemia

> **NCT01368757** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Arbeitsgemeinschaft medikamentoese Tumortherapie** · enrollment: 30 (estimated)

## Conditions studied

- Chronic Myelomonocytic Leukemia

## Interventions

- **DRUG:** Revlimid

## Key facts

- **NCT ID:** NCT01368757
- **Lead sponsor:** Arbeitsgemeinschaft medikamentoese Tumortherapie
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-06
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2015-03-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01368757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01368757, "Lenalidomide in Patients With Chronic Myelomonocytic Leukemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01368757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*